Literature DB >> 12432782

Neuroprotection for Parkinson's disease using viral vector-mediated delivery of GDNF.

Jodi L McBride1, Jeffrey H Kordower.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12432782     DOI: 10.1016/S0079-6123(02)38091-9

Source DB:  PubMed          Journal:  Prog Brain Res        ISSN: 0079-6123            Impact factor:   2.453


× No keyword cloud information.
  5 in total

1.  Organically modified silica nanoparticles: a nonviral vector for in vivo gene delivery and expression in the brain.

Authors:  Dhruba J Bharali; Ilona Klejbor; Ewa K Stachowiak; Purnendu Dutta; Indrajit Roy; Navjot Kaur; Earl J Bergey; Paras N Prasad; Michal K Stachowiak
Journal:  Proc Natl Acad Sci U S A       Date:  2005-07-28       Impact factor: 11.205

2.  Large animal models are critical for rationally advancing regenerative therapies.

Authors:  Dustin R Wakeman; Andrew M Crain; Evan Y Snyder
Journal:  Regen Med       Date:  2006-07       Impact factor: 3.806

3.  Tricyclic antidepressant treatment evokes regional changes in neurotrophic factors over time within the intact and degenerating nigrostriatal system.

Authors:  Katrina L Paumier; Caryl E Sortwell; Lalitha Madhavan; Brian Terpstra; Brian F Daley; Timothy J Collier
Journal:  Exp Neurol       Date:  2015-02-12       Impact factor: 5.330

4.  AAV2-mediated gene transfer of GDNF to the striatum of MPTP monkeys enhances the survival and outgrowth of co-implanted fetal dopamine neurons.

Authors:  J D Elsworth; D E Redmond; C Leranth; K B Bjugstad; J R Sladek; T J Collier; S B Foti; R J Samulski; K P Vives; R H Roth
Journal:  Exp Neurol       Date:  2008-02-15       Impact factor: 5.330

5.  Neurturin-mediated ret activation is required for retinal function.

Authors:  Milam A Brantley; Sanjay Jain; Emily E Barr; Eugene M Johnson; Jeffrey Milbrandt
Journal:  J Neurosci       Date:  2008-04-16       Impact factor: 6.167

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.